Featured Trial:
Melanoma Treatment

Featured Trial:
Head and Neck Cancer Treatment

Featured Trial:
Breast Cancer Treatment

Featured Trial:
Sarcoma Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Resources for Active Trials

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
PRO Research Overview

Specialty Presentation:
Implementation Science

Latest News

October 10, 2024

Categories

News Stories

Women in Medicine Month: Celebrating Women Advancing Radiology

September 26, 2024

Categories

The Fall 2024 advocacy blog Considering Clinical Trials is now available

September 20, 2024

Categories

Announcements

The September 2024 News from ECOG-ACRIN blog is now available

September 18, 2024

Categories

Press Releases

Press Release: Cancer Cooperative Group leaders propose a re-engineering of the nation’s correlative science program for cancer

September 10, 2024

Categories

Press Releases

Press Release: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Tweets

ECOG-ACRIN Cancer Research Group Follow 7,322 6,231

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

; ECOG-ACRIN Cancer Research Group @eaonc ·

8 Oct 1843713385675796530

Could chemotherapy given both before and after surgery improve outcomes for patients with #GallbladderCancer (compared to chemo given only after surgery)? #ClinicalTrial EA2197/OPT-IN aims to find out. More info: https://bit.ly/EA2197 cc: @skmaithel @WinshipAtEmory

Reply on Twitter 1843713385675796530 Retweet on Twitter 1843713385675796530 0 Like on Twitter 1843713385675796530 0 Twitter 1843713385675796530

; ECOG-ACRIN Cancer Research Group @eaonc ·

8 Oct 1843683226709111026

Help potentially improve the future of #HeadAndNeckCancer treatment. Take part in clinical study EA3191 for patients with squamous cell carcinoma of the head and neck (#HNSCC) that has come back. Learn more: https://bit.ly/ea3191-study #HNCA

Reply on Twitter 1843683226709111026 Retweet on Twitter 1843683226709111026 0 Like on Twitter 1843683226709111026 0 Twitter 1843683226709111026

; ECOG-ACRIN Cancer Research Group @eaonc ·

8 Oct 1843667945026707537

In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: http://bit.ly/ComboMATCH #PrecisionMedicine #ClinicalTrial

Reply on Twitter 1843667945026707537 Retweet on Twitter 1843667945026707537 1 Like on Twitter 1843667945026707537 3 Twitter 1843667945026707537

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).